Lv7
3820 积分 2023-03-30 加入
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
1个月前
已完结
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis
1个月前
已完结
Efficacy and safety of cyclin‐dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real‐world experience
1个月前
已完结
Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study
1个月前
已完结
First‐line CDK4/6 inhibitor‐based combinations for HR+/HER2– advanced breast cancer: A Bayesian network meta‐analysis
1个月前
已完结
Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2− Advanced or Metastatic Breast Cancer
1个月前
已完结
THE RISK OF QTC PROLONGATION IN PATIENTS USING CYCLIN-DEPENDENT KINASE 4/6 IN ADVANCED BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
1个月前
已完结
CO31 Clinical Benefits of CDK 4/6 Inhibitors in HR+ HER2- Metastatic Breast Cancer: A Systematic Review
1个月前
已完结
Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy
2个月前
已完结
Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy
2个月前
已完结
皖公网安备34019202002308
